All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 7 read as filed from the record and 2 are SI estimates, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
1 warning event since 2017; the latest 2023-06-22.
From the record
Medicinova Inc's filings since 2017 show 1 warning event: a notice about its exchange listing (8-K item 3.01, the latest 2023-06-22) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
-43.6% a year over 3 filed years; profitable in 0 of 5.
From the record
Medicinova Inc's 3 filed years say what it did: revenue went from $4 million in fiscal 2021 to $410 thousand in fiscal 2025, down 43.6% a year; it rose in 0 of 2 years; the deepest fall was 90% from fiscal 2021 to fiscal 2025; net income was positive in 0 of 5 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 8.9/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Medicinova Inc's shareholder treatment is put at 8.9 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 11% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -29%: lost 29¢ per shareholder dollar. Leverage 9%: owes 9¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Medicinova Inc lost about 29 cents for every dollar of shareholders' money. Leverage: it owed about 9 cents per dollar of assets, and net share issuance: its share count was unchanged over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
bottom 15% of 315 in its family; net margin -2928.8%.
From the record
Medicinova Inc's standing among 315 graded names in its industry family: revenue of $410 thousand in fiscal 2025 ranks in the bottom 15% by size; a net margin of -2928.8% ranks in the bottom 20%; revenue growth of -43.6% a year over the last 2 filed years ranks in the bottom 12% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
top 15% of 315 in its family for leadership; chief executive since 2006.
From the record
Medicinova Inc's leadership, from its insiders' filings and its current reports: the chief executive on the record is Iwaki, Yuichi (President and CEO, as filed), filing under that title since 2006-01-06, 20.9 years (top 1% of its family); the 5 officers and directors filing in the last fifteen months have been on the record a median of 15.1 years (top 2%); 2 officer or director changes were reported on Form 8-K since 2023-11-13, against the 5 people in charge now (top 42%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
top 41% of 273 in its family for room to expand.
From the record
Medicinova Inc's room to grow, from the newest filed statements (fiscal 2025): cash of $31 million against no long-term debt tagged leaves 67.6% of its assets as net cash, top 24% of its family; cash from operations less capital spending is -2395.4% of revenue (bottom 16%); research spending of 1635.5% of revenue (top 15%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
bottom 41% of 306 in its family for growth drivers.
From the record
Medicinova Inc's growth drivers, from the filed years to fiscal 2025: revenue grew -43.6% a year over the last three filed years against -43.6% over all 3, speeding up (top 40% of its family); the newest year grew -36% (bottom 22%); research spending grew -8.3% a year (bottom 33%); capital spending grew -16.7% a year (bottom 49%) (its annual reports). Medicinova Inc tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
SI estimate 5.3/10, confidence 20 of 100 (family median).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Medicinova Inc's expectations vs reality is put at 5.3 of 10 with a confidence of 20 of 100, because the record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change, so the desk assumes the typical reading of its industry family, the median of 234 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made